ABSORB Bioresorbable Scaffold vs. Xience Metallic Stent for Prevention of Restenosis in Patients at High Risk of Restenosis

Category Primary study
Registry of Trialsclinicaltrials.gov
Year 2015
The primary objectives of this trial are: In patients at high-risk for restenosis, * To assess non-inferiority of the everolimus-eluting bioresorbable scaffold (BRS) to the everolimus eluting cobalt chromium metallic stent (EES) in target lesion failure (TLF) at 1 year * To assess superiority of the BRS to the EES in TLF between 3 and 7 years
Epistemonikos ID: 90bed18a88b12add7d0f59af763cea814e60300b
First added on: May 12, 2024